ARTICLE | Clinical News
House dust mites sublingual immunotherapy tablet: Phase II/III data
February 24, 2014 8:00 AM UTC
Stallergenes said partner Shionogi reported data from the double-blind, Japanese Phase II/III S-524101 trial showing that house dust mites sublingual immunotherapy tablet met the primary endpoint of i...